Lumos Pharma, Inc. (NASDAQ:LUMO) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET

Company Participants

Lisa Miller – Senior Director of Investor Relations

Rick Hawkins – Chief Executive Officer and Chairman

Lori Lawley – Chief Financial Officer

John McKew – President and Chief Scientific Officer

Duke Pitukcheewanont – Senior Vice President of Global Clinical Development and Medical Affairs

Conference Call Participants

Yasmeen Rahimi – Piper Sandler

Leland Gershell – Oppenheimer

Ed White – H.C. Wainwright

Catherine Novack – Jones Trading

Pete Stavropoulos – Cantor Fitzgerald

Operator

Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I'll now turn the call over to Lisa Miller, Senior Director of Investor Relations.

Lisa Miller

Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release we issued this afternoon, and in our Form 10-Q, which may be accessed from the Investors page of the company's website. Speaking on today's call will be Rick Hawkins, CEO and Chairman; and Lori Lawley, our CFO; John McKew, our President and Chief Scientific Officer; as well as Dr. Duke Pitukcheewanont, our Senior Vice President of Global Clinical Development and Medical Affairs, will join for question-and-answer session.

I will now turn the call over to Rick.

Rick Hawkins

Well, thank you, Lisa, and good afternoon everyone. After the market closed today, we issued a press release announcing our second quarter 2023 financial results and provided an update on our clinical programs. As is our practice, we'll keep our prepared remarks on today's call brief, so we can maximize the time available for Q&A. I'll touch on the highlights from the quarter in recent weeks before turning it over to Lori for review of our financial results. Then John McKew and Dr. Pitukcheewanont, or Dr. Duke as we call him, will join us to answer your questions. Dr. Duke joined us about a year and a half ago from Ascendis, where he worked on their long-acting injectable growth hormone therapy or therapeutic to approval. He is also President of the Human Growth Foundation. And with his contacts and understanding of the potential of an oral therapeutic in this space, Duke has been instrumental in advancing the enrollment in our OraGrowtH210 trial and in preparation for our Phase 3 trial in Pediatric Growth Hormone Deficiency, or PGHD.